KRT88P and graft versus host disease: Tomblyn et al. [22] reported that, if the HSCT recipient is anti-HBc-positive and anti-HBs-positive, the risk of HBV reactivation is considered low during chemotherapy/conditioning, but it is thought to be higher following prolonged treatment with prednisone for graft-versus-host disease.